AbbVie ລາຍງານລາຍໄດ້ລວມ, ຮັດກຸມການຊີ້ນໍາ, ຍົກເງິນປັນຜົນປະຈໍາໄຕມາດ

• ບໍລິສັດ AbbVie Inc (NYSE: ເອບີບີວີ) ລາຍ​ງານ​ Q3 adjusted EPS of $3.66, up 29.3% Y/Y and beating the consensus of $3.59.

• Overall sales increased 3.3% Y/Y (5.4% on an operational basis) to $14.81 billion, missing the consensus of $14.96 billion.

• The immunology portfolio generated $7.65 billion in sales, +14.6% (+16.4% on an operational basis). Humira sales increased 2.5% to $5.56 billion. Skyrizi sales reached $1.39 billion (+75.4% Y/Y), and Rinvoq jumped 53.5% to $695 million.

• Hematologic oncology portfolio sales were $1.65 billion, down 11.7% (-9.9% on an operational basis). Imbruvica sales decreased 17.4% to $1.34 billion. Venclexta revenues were up 4.5% to $515 million.

• Sales from the neuroscience portfolio reached $1.67 billion, +6.7%. Aesthetics portfolio sales increased 4% (+8.1% on an operational basis) to $1.30 billion, with $637 million in Botox sales for cosmetic uses.

• ເງິນປັນຜົນ: AbbVie increased the quarterly dividend by 5% from $1.41 per share to $1.48 per share.

• ການແນະນໍາ: AbbVie confirms FY22 adjusted EPS guidance and narrows the range from $13.76 – $13.96 to $13.84 – $13.88, compared to the consensus of $13.86.

• ລາຄາປະຕິບັດງານ: ABBV shares are up 0.71% at $150.89 during the premarket session on the last check Friday.

ເບິ່ງເພີ່ມເຕີມຈາກ Benzinga

ຢ່າພາດການແຈ້ງເຕືອນແບບສົດໆໃນຫຸ້ນຂອງເຈົ້າ – ເຂົ້າຮ່ວມ Benzinga Pro ສໍາລັບການຟຣີ! ລອງໃຊ້ເຄື່ອງມືທີ່ຈະຊ່ວຍໃຫ້ທ່ານລົງທຶນຢ່າງສະຫຼາດຂຶ້ນ, ໄວຂຶ້ນ, ແລະດີກວ່າ.

©ປີ 2022 Benzinga.com. Benzinga ບໍ່ໃຫ້ ຄຳ ແນະ ນຳ ດ້ານການລົງທືນ. ທິການ.